Repurposing of Drugs for Cardiometabolic Disorders: An Out and Out Cumulation
Horm Metab Res 2023; 55: 7-24 DOI: 10.1055/a-1971-6965Cardiometabolic disorders (CMD) is a constellation of metabolic predisposing
factors for atherosclerosis such as insulin resistance (IR) or diabetes mellitus
(DM), systemic hypertension, central obesity, and dyslipidemia. Cardiometabolic
diseases (CMDs) continue to be the leading cause of mortality in both developed
and developing nations, accounting for over 32% of all fatalities
globally each year. Furthermore, dyslipidemia, angina, arrhythmia, heart
failure, myocardial infarction (MI), and diabetes mellitus are the major causes
of death, accounting for an estimated 19 million deaths in 2012. CVDs will kill
more than 23 million individuals each year by 2030. Nonetheless, new drug
development (NDD) in CMDs has been increasingly difficult in recent decades due
to increased costs and a lower success rate. Drug repositioning in CMDs looks
promising in this scenario for launching current medicines for new therapeutic
indications. Repositioning is an ancient method that dates back to the 1960s and
is mostly based on coincidental findings during medication trials. One
significant advantage of repositioning is that the drug’s safety profile
is well known, lowering the odds of failure owing to undesirable toxic effects.
Furthermore, repositioning takes less time and mone...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Wasim, Rufaida Ansari, Tarique Mahmood Siddiqui, Mohammed Haris Ahsan, Farogh Shamim, Arshiya Singh, Aditya Shariq, Mohammad Anwar, Aamir Siddiqui, Aquib Rehanullah Parveen, Saba Tags: Review Source Type: research
More News: Arrhythmia | Cardiology | Diabetes | Diabetes Mellitus | Eating Disorders & Weight Management | Endocrinology | Heart | Heart Attack | Heart Failure | Hormones | Hypertension | Insulin | Obesity | Toxicology